[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-surgery":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,52,75,104,135,159,182,202,237,266,295,315,346,370,394,423,453,481,508,525,545,567,594,621,649],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100573228","phase-1-surgery-after-verifying-existing-disease-in-locally-advanced-operable-lung-cancer-a-pilot-study-100573228",false,"NCT06743555","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer (SAVED LUNG Study): A Pilot Study","SAVED LUNG","Inclusion Criteria:\n\n* \\> 18 years of age\n* The participant has provided documented informed consent for the trial.\n* Histologically confirmed (by core biopsy) NSCLC and confirmed clinical stages II-III (excluding N2) NSCLC (AJCC 8th edition) amenable to receive neoadjuvant chemo-immunotherapy defined by: nivolumab 3mg\u002Fkg Q3W in combination with platinum doublet chemotherapy (cisplatin or carboplatin with paclitaxel or pemetrexed Q3W) for 3 cycles.\n* PD-L1 tumor proportion score \\>50%\n* Has no history of immunodeficiency, HBV, HCV, HIV.\n* For female participants:\n\n  1. Has no active pregnancy (Refer to \"Female participants\").\n  2. For a woman of child-bearing potential (WOCBP), use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 180 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore for her own use for the purpose of reproduction during this period.\n  3. A WOCBP must have a negative highly sensitive pregnancy test (\\[urine or serum\\] as required by local regulations) within either 24 hours (urine) or 72 hours (serum) before the first dose of study intervention.\n  4. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has adequate hematological, renal and hepatic function per Investigator discretion required for platinum-doublet chemotherapy plus immunotherapy.\n* Has signed the written consent.\n\nExclusion Criteria:\n\n* Has one of the following tumor locations\u002Ftypes:\n\n  1. NSCLC involving the superior sulcus\n  2. Large cell neuro-endocrine cancer (LCNEC)\n  3. Sarcomatoid tumor\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has had an allogenic tissue\u002Fsolid organ transplant.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Has a known additional malignancy that is progressing or requires active treatment within the past (5 years). Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, bladder carcinoma, or carcinoma in situ (eg, in situ cervical cancer or breast carcinoma) that have undergone potentially curative therapy are not excluded.","ALL","18 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.",[28,29,30,31,32],"Non-Small Cell Lung Cancer","Immunotherapy","Neoadjuvant Therapy","Thoracic Surgery","Complete Response",[34,35,36,37,38],"NSCLC","Neoadjuvant immunotherapy","Complete response","Surveillance","PD-L1","NOT_YET_RECRUITING","2026-08-13",{"date":42,"type":43},"2026-08-14","ACTUAL",{"date":45,"type":22},"2026-10-01",{"date":47,"type":22},"2032-02",{"name":49,"class":50},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100650933","comparison-of-liposomal-bupivacaine-paravertebral-nerve-block-versus-intercostal-nerve-block-on-postoperative-glycemic-variability-in-patients-undergoing-minimally-invasive-pulmonary-resection-a-randomized-controlled-non-inferiority-trial-100650933","NCT07754916","Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n1. Aged 18-70 years, with American Society of Anesthesiologists (ASA) physical status I-III, scheduled for uniportal or multiportal video-assisted thoracoscopic (VATS) minimally invasive pulmonary resection under general anesthesia.\n2. Planned to receive liposomal bupivacaine regional block analgesia under direct thoracoscopic visualization.\n3. Body mass index (BMI) 18-30 kg\u002Fm².\n4. Willing and able to cooperate with the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Regularly taking beta-blockers (for ≥2 weeks) or long-term use of high-dose glucocorticoids (prednisone ≥20 mg\u002Fday for \\>2 weeks).\n2. Known history of diabetes mellitus, or regular use of glucose-lowering agents (oral agents or insulin) before surgery.\n3. Planned postoperative admission to the intensive care unit (ICU).\n4. Concurrent severe cardiac (New York Heart Association class III or higher), hepatic (e.g., cirrhosis), or renal insufficiency (glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²), or neuropsychiatric disorders.\n5. Contraindications to regional block or to any study medication, including but not limited to infection or tumor invasion at the puncture site, coagulation disorders, or allergy to any drug used in the study.\n6. Alcohol dependence: meeting the DSM-5 criteria for severe alcohol use disorder (AUD), or clinically judged as alcohol dependence (regardless of liver function status).\n7. Pregnancy or lactation (for men and women of childbearing potential, effective contraception is required until 3 months after surgery, and donation of sperm or eggs is prohibited).\n8. Participation in another interventional drug trial.\n9. Regular use of analgesics for acute or chronic pain within 2 weeks before surgery.\n10. Concurrent severe infection.\n11. Prior ipsilateral intrathoracic surgery or severe pleural adhesions (estimated to preclude successful thoracoscopic visualization and completion of the block).\n12. Psychiatric or cognitive disorders that would impair the ability to cooperate with postoperative follow-up.\n13. Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the trial (for medical or safety reasons).","70 Years",{"count":60,"type":22},64,[62],"NA","In this randomized controlled non-inferiority trial, we will test whether liposomal bupivacaine intercostal nerve block is non-inferior to paravertebral nerve block for the coefficient of variation (CV) of glucose during the 0- to 48-hour postoperative period, using a non-inferiority margin of Δ = 0.025 for the absolute CV difference. We will also compare the two blocks regarding their effects on postoperative glucose, autonomic function, stress, insulin resistance, acute pain, recovery quality, procedure duration, complications, and hemodynamic stability.",[31,65],"Glycemic Variability","2026-08-09",{"date":68,"type":43},"2026-08-12",{"date":70,"type":22},"2026-08-01",{"date":72,"type":22},"2027-02-28",{"name":74,"class":50},"Xiangya Hospital of Central South University",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":51},"100639567","ct-guided-vs-conventional-dlt-sizing-in-thoracic-surgery-100639567","NCT07575763","CT-Guided vs Conventional DLT Sizing in Thoracic Surgery","CT-Guided Versus Traditional Selection of Double-Lumen Tube Size for One-Lung Ventilation in Thoracic Surgery: A Prospective Study","CTDLT-SIZE","Inclusion Criteria:\n\n1. Adult patients (≥18 years) scheduled for elective thoracic surgery requiring one-lung ventilation.\n2. Availability of preoperative thoracic CT imaging.\n3. Procedures requiring placement of a left-sided DLT.\n4. Patient who has a normal pulmonary function test.\n\nExclusion Criteria:\n\n1. Previous tracheal surgery\n2. Patient with difficult airway whom need bronchial blocker.\n3. Emergency thoracic procedures.\n4. Incomplete intraoperative or imaging data.\n5. Patient with severe obstruction or restriction.\n6. Pediatric patient",{"count":84,"type":22},100,[62],"This is a prospective, randomized, single-blinded controlled trial designed to compare CT-guided versus conventional methods for selecting double-lumen tube (DLT) size in patients undergoing thoracic surgery requiring one-lung ventilation",[31,88],"One-lung Ventilation",[90,91,92,93],"Double-lumen tube","Thoracic anesthesia","CT-guided intubation","One-lung ventilation","RECRUITING","2026-08-04",{"date":97,"type":43},"2026-08-07",{"date":99,"type":43},"2026-05-15",{"date":101,"type":22},"2028-08-01",{"name":103,"class":50},"King Hussein Cancer Center",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":51},"100649440","analgesia-with-transdermal-buprenorphine-patch-in-adults-undergoing-video-assisted-thoracoscopic-surgery-100649440","NCT07733128","Analgesia With Transdermal Buprenorphine Patch in Adults Undergoing Video-Assisted Thoracoscopic Surgery","Analgesia With a 5 mcg\u002FHour Transdermal Buprenorphine Patch as Part of Multimodal Analgesia in Adults Undergoing Unilateral Video-Assisted Thoracoscopic Surgery: A Triple-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled for elective unilateral video-assisted thoracoscopic surgery (VATS).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to buprenorphine or any component of the transdermal patch.\n* Chronic opioid use before surgery.\n* Severe hepatic impairment.\n* Pregnancy or breastfeeding.\n* Inability to complete postoperative pain assessments.\n* Any condition that, in the investigator's opinion, could interfere with study participation or outcome assessment.",{"count":112,"type":22},90,[62],"Postoperative pain remains a major challenge after video-assisted thoracoscopic surgery (VATS), despite the use of multimodal analgesia. This randomized, triple-blind, placebo-controlled clinical trial will evaluate whether adding a 5 mcg\u002Fhour transdermal buprenorphine patch to the standard multimodal analgesic regimen reduces postoperative pain in adults undergoing unilateral VATS. Participants will be randomly assigned to receive either transdermal buprenorphine or placebo in addition to standard analgesia. Postoperative pain will be assessed at 24, 48, and 72 hours and 7 days after surgery. Secondary outcomes include opioid rescue requirements, length of hospital stay, postoperative nausea and vomiting, pruritus, and urinary retention.",[116,31,117],"Postoperative Pain","Video-Assisted Thoracoscopic Surgery",[119,120,121,117,122,116,123,31,124,125],"Buprenorphine","Transdermal Patch","Multimodal Analgesia","VATS","Randomized Controlled Trial","Acute Pain","Opioid Analgesia","2026-07-24",{"date":128,"type":43},"2026-07-29",{"date":130,"type":43},"2026-03-01",{"date":132,"type":22},"2027-07",{"name":134,"class":50},"Clínica Dávila",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":51},"100649401","rehabilitation-with-wearable-monitors-for-post-lung-cancer-surgery-100649401","NCT07733492","Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery","A Clinical Trial of Postoperative Rehabilitation for Non-Small Cell Lung Cancer Based on Wireless Wearable Mobile Monitoring Devices","WEAR-LUNG","Inclusion Criteria:\n\n* Age ≥18 and ≤85 years\n* Histopathologically confirmed primary non-small cell lung cancer (NSCLC) who have undergone elective curative-intent lobectomy or segmentectomy\n* Planned discharge between postoperative day 2 and day 7, and judged by the investigator to be clinically stable and suitable for home-based rehabilitation\n* Able to operate a smartphone application and wearable devices independently or with caregiver assistance\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Pre-existing long-term home oxygen therapy, or severe resting respiratory dysfunction\n* Concurrent severe, uncontrolled cardiovascular disease, severe hepatic insufficiency, or severe renal insufficiency\n* Other diseases or conditions that significantly affect motor function or compliance\n* Known or suspected contact allergy to medical adhesives or materials used in the wearable devices\n* Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation","85 Years",{"count":145,"type":22},126,[62],"This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial evaluating whether a wireless wearable mobile monitoring device combined with a digital rehabilitation program improves pulmonary function at 90 days postoperatively in patients undergoing curative-intent lobectomy or segmentectomy for non-small cell lung cancer (NSCLC).\n\nEligible participants will be randomized to either the intervention group or the control group. Both groups receive standard postoperative rehabilitation education. The intervention group additionally receives a wearable device (chest patch or wristband) for continuous monitoring of SpO₂, heart rate, respiratory rate, and physical activity, along with a smartphone-based digital rehabilitation program including individualized exercise prescriptions (aerobic, resistance, and inspiratory muscle training), daily symptom diaries, and remote feedback with threshold-triggered alerts for up to 90 days after discharge. The control group receives standard rehabilitation education with routine follow-up.\n\nThe primary endpoint is the between-group difference in FEV1% predicted at postoperative day 90, analyzed using ANCOVA adjusted for baseline FEV1% predicted. Secondary endpoints include FVC% predicted, 6-minute walk distance, daily step count, SpO₂ \\\u003C90% time burden, quality of life (EORTC QLQ-C30\u002FLC13, mMRC), 90-day readmission and emergency visit rates, and safety outcomes.\n\nA total of 126 participants (63 per group) will be enrolled. The study is being conducted at West China Hospital of Sichuan University from June 2026 to October 2027.",[149,150,31],"Non-Small Cell Lung Cancer (NSCLC)","Rehabilitation",[149,150,31],{"date":128,"type":43},{"date":154,"type":22},"2026-08-31",{"date":156,"type":22},"2028-08-31",{"name":158,"class":50},"West China Hospital",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":51},"100610516","biofilm-on-chest-drains-after-thoracic-surgery-clinical-impact-and-antibiotic-resistance-100610516","NCT07228598","Biofilm on Chest Drains After Thoracic Surgery: Clinical Impact and Antibiotic Resistance","Biofilm Formation on Thoracic Drains: Clinical Significance and Association With Antibiotic Resistance","Inclusion Criteria:\n\n* Age 18 years and older\n* Undergoing elective thoracic surgery requiring chest drain placement\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of active infection prior to surgery\n* Emergency thoracic surgery\n* Immunosuppressed patients (e.g., neutropenia, advanced malignancy, organ transplantation)\n* Patients receiving systemic antibiotic therapy at the time of drain removal\n* Drainage for empyema or pre-existing pleural infection\n* Presence of extrathoracic infection focus\n* Refusal or inability to provide informed consent",{"count":167,"type":22},180,"30 Days","OBSERVATIONAL","This prospective observational study aims to investigate the frequency and clinical significance of biofilm formation on thoracic chest drains used after thoracic surgery. Biofilms are structured bacterial communities that adhere to surfaces and can promote infection and antibiotic resistance. In this study, small samples from the tips of chest drains will be collected under sterile conditions at the time of drain removal and analyzed in the microbiology laboratory.\n\nThe main objectives are to evaluate the relationship between the duration of chest drain placement and the presence of biofilm, and to identify the antibiotic resistance profiles of microorganisms isolated from these biofilms. Secondary outcomes include the association between biofilm formation, postoperative infections (such as empyema or wound infection), and the length of hospital stay.\n\nThis study will be conducted at Ondokuz Mayıs University Faculty of Medicine, Department of Thoracic Surgery, in collaboration with the Department of Microbiology. The findings are expected to contribute to better understanding of optimal drain management and infection prevention strategies after thoracic surgery.",[172,31,173,174],"Biofilms","Postoperative Infection","Antibiotic Resistance, Bacterial","2026-07-23",{"date":126,"type":43},{"date":178,"type":43},"2025-10-01",{"date":45,"type":22},{"name":181,"class":50},"Caner İşevi, MD",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":51},"100644852","continuous-erector-spinae-block-versus-thoracic-epidural-analgesia-for-the-prevention-of-chronic-pain-following-thoracotomy-a-retrospective-study-100644852","NCT07677540","Continuous Erector Spinae Block Versus Thoracic Epidural Analgesia for the Prevention of Chronic Pain Following Thoracotomy: a Retrospective Study","Inclusion Criteria:\n\n1\\. Ages 18-65 years 2. Presenting for elective thoracic surgery under general anesthesia. 3. Undergoing either ESP or TEA prior to surgery.\n\n\\-\n\nExclusion Criteria:Patients were excluded if they met any of the following criteria:\n\n1\\. Any CNS and\u002For psychiatric disease. 2. Patients who are unable to complete the pain survey for any reason. 3. Patients who had baseline chronic pain around the surgical incision.\n\n\\-","99 Years",{"count":190,"type":22},34,"Post-thoracotomy pain syndrome (PTPS) is a prevalent complication that significantly impacts patients' quality of life, with reported incidence ranging from 25% to 90%. This study evaluated the effectiveness of continuous erector spinae plane (ESP) block compared to thoracic epidural analgesia (TEA), the current gold standard, in preventing PTPS. Our goal was to compare the incidence of PTPS between patients who received ESP block and those who underwent TEA. Additional goals included assessing postoperative pain levels, analgesic consumption, and complications related to the anesthesia techniques.",[31],"2026-06-24",{"date":195,"type":43},"2026-06-30",{"date":197,"type":43},"2023-09-12",{"date":199,"type":22},"2026-07-31",{"name":201,"class":50},"Meir Medical Center",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":211,"conditions":212,"keywords":227,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":51},"100642312","risk-factors-of-atrial-fibrillation-after-cardiac-surgery-100642312","NCT07625033","Risk Factors of Atrial Fibrillation After Cardiac Surgery","PFAS","Inclusion Criteria:\n\n* age \\>18\n* having undergone a scheduled cardiac surgery in the study center\n* having agreed to the reuse of their hospital care data\n\nExclusion Criteria:\n\n* Atrial fibrillation at the admission in hospital.",{"count":210,"type":22},918,"Supraventricular arrhythmias complicate more than 40% of cardiac surgeries and are associated with an increased risk of bleeding, stroke, heart failure, and death. Preventing the occurrence of these arrhythmias is a major challenge. This study aims to investigate risk factors and protective factors regarding atrial fibrillation and other iatrogenic cardiac arrhythmias after cardiac surgery, particularly innovative anesthetic strategies such as stellar ganglion blockade which have been recently implemented in our center.",[213,214,31,215,216,217,218,219,220,221,222,223,224,225,226],"Cardiac Surgery","Peri Operative Medicine","Cardiopulmonary Bypass","Coronary Artery Bypass","Heart Valve Prosthesis Implantation","Aortic Valve Replacement","Perioperative Medicine","Preoperative Care","Intraoperative Care","Postoperative Care","Enhanced Recovery After Surgery","Anesthesia","Cardiac Anesthesia","Intensive Care Unit",[228],"Stellar Ganglion Blockade, SGB, cardiac surgery","2026-06-23",{"date":231,"type":43},"2026-06-25",{"date":233,"type":22},"2026-07-01",{"date":233,"type":22},{"name":236,"class":50},"Centre Hospitalier Régional Metz-Thionville",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":51},"100584783","influence-of-the-culture-care-program-on-patient-mobility-after-thoracic-or-abdominal-surgery-a-mixed-methods-study-100584783","NCT06893848","Influence of the Culture Care Program on Patient Mobility After Thoracic or Abdominal Surgery: a Mixed-methods Study","Culture Care Program: a Mixed-methods Study Evaluating the Effect of an Innovative In-hospital Experience on Patient Mobility After Thoracic or Abdominal Surgery","CULTURECARE","Inclusion Criteria:\n\n* Admission to Surgical Units in the Surgical Department of the Hôpital de Neuchâtel implementing the Culture Care program.\n* Elective thoracic or abdominal surgery with an expected hospital stay of at least 2 days (i.e. discharge on postoperative day 3).\n* Neurocognitive and physical ability to complete questionnaires and individual participation in the Culture Care program.\n* Full capacity of discernment and signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Outpatient surgery.\n* Emergency surgery.\n* Mobility severely impaired prior to surgery: patients with 1 or 2 lower-limb amputations, patients with wheelchair mobility only, neurodegenerative diseases.\n* Bed restiction between POD 1 and POD 5 for medical reasons, i.e. surgery, post-operative complications or other pre-existing cardiorespiratory, neurological or orthopedic reasons.\n* Transfer to ICU\n* Only during the Culture Care phase, an unplanned transfer to another unit that does not have the Culture Care program (e.g. Medicine units).\n* Technical problem with the accelerometer (e.g. disfunctioning battery).\n* Allergic reaction to any dressing used to attach the accelerometer.\n* End-of-life patients.",true,{"count":247,"type":22},204,[62],"A sedentary behavior in the postoperative phase has a negative impact on recovery from various types of surgery (e.g. abdominal, pulmonary, cardiac or esophageal). In fact, sedentary behavior in the days following surgery is associated with an increased risk of postoperative complications, longer hospital stays and, consequently, higher healthcare costs. Stimulating early mobilization and increasing the level of physical activity after surgery therefore remains a relevant current challenge. The Culture Care program will propose a new experience of the hospital towards an attractive and stimulating intrahospital environment, including art and culture. The hypothesis is that the innovative, positive hospital experience offered by the Culture Care program could contribute to increasing patients' mobility in the postoperative phase and thus reduce the sedentary behaviour compared with a control group included before the implementation of the program.\n\nThe aim of this study is to explore the effect of the Culture Care program (Control group versus Culture Care group) on the mobility of patients hospitalized after thoracic or abdominal surgery, by determining the level of prediction in relation to the influencing covariates reported in the literature.\n\nThe first quantitative part of this research project will compare the mobility of patients hospitalized after surgery, before (control group) and after the implementation of the Culture Care program (Culture Care group). Patients will be asked to wear an accelerometer for the first five post-operative days, and to complete three questionnaires (psychological well-being, physical recovery, perception of their mobility).\n\nHealthcare workers will be asked to complete a survey on their readiness to stimulate patients' mobility before and after the Culture Care program.\n\nThe second part will be qualitative including individual semi-structured interviews with patients and healthcare workers during the Culture Care program, to gather their experiences.",[31,251,252,253],"Abdominal Surgery Patients","Hospital Mobility","Mobility Limitation",[255,256,257,258],"Physical activity","Postoperative recovery","Accelerometer","Early mobilization",{"date":193,"type":43},{"date":261,"type":43},"2025-03-10",{"date":263,"type":22},"2027-12",{"name":265,"class":50},"Haute Ecole ARC Sante",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":51},"100641532","spsip-versus-riss-block-in-volume-preserving-vats-100641532","NCT07655336","SPSIP Versus RISS Block in Volume-Preserving VATS","Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal-Subserratus Plane Block on Postoperative Analgesia and Respiratory Functions in Volume-Preserving Video-Assisted Thoracoscopic Surgery: A Prospective Randomized Controlled Trial","SRVATS","Inclusion Criteria:\n\n* Patients scheduled for elective biportal video-assisted thoracoscopic surgery (VATS) with lung parenchyma-preserving thoracic procedures under general anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Age between 18 and 75 years\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Use of anticoagulant or antiplatelet therapy\n* Bleeding diathesis\n* Known allergy to local anesthetics\n* Infection at the planned block site\n* Severe chronic pulmonary disease or advanced respiratory failure (e.g., severe COPD or restrictive lung disease)\n* Cognitive impairment preventing reliable NRS assessment\n* Pregnancy or lactation\n* Chronic opioid use (regular use for ≥3 months)\n* Severe hepatic or renal failure\n* Refusal to participate\n* Technical failure or unsuccessful regional block\n* Conversion to open thoracotomy during surgery","75 Years",{"count":276,"type":22},84,[62],"This prospective randomized controlled study aims to compare the effects of Serratus Posterior Superior Intercostal Plane (SPSIP) block and Rhomboid Intercostal and Subserratus (RISS) block on postoperative pain, respiratory function, and recovery quality in patients undergoing volume-preserving video-assisted thoracoscopic surgery (VATS). Eighty-four patients will be randomized in a 1:1 ratio to receive either SPSIP block or RISS block. The primary outcome is the incidence of somatic pain at the chest drain insertion site at postoperative 2 hours. Secondary outcomes include pain scores, opioid consumption, quality of recovery, diaphragmatic function, pulmonary function, rescue analgesic requirements, postoperative nausea and vomiting, and block-related complications.",[116,31],[281,122,282,283,284,285],"Video-Assisted Thoracic Surgery","Serratus Posterior Superior Intercostal Plane Block","Rhomboid Intercostal and Subserratus Block","Diaphragmatic Excursion","Peak Expiratory Flow","2026-06-18",{"date":288,"type":43},"2026-06-22",{"date":286,"type":43},{"date":291,"type":22},"2026-12",{"name":293,"class":294},"Ferit Yetik","OTHER_GOV",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":51},"100642251","cerebral-oximetry-guided-low-fio2-strategies-in-thoracic-surgery-100642251","NCT07659483","Cerebral Oximetry-Guided Low FiO2 Strategies in Thoracic Surgery.","Safety and Efficacy of Cerebral Oximetry-Guided Low FiO2 Strategies in Thoracic Surgery","Inclusion Criteria:\n\n* Patients aged 18 years or older. Scheduled for elective thoracic surgery requiring one-lung ventilation (OLV). American Society of Anesthesiologists (ASA) Physical Status classification I-III.\n\nExclusion Criteria:\n\n* History of cerebrovascular disease. Left ventricular ejection fraction Pulmonary hypertension. Interstitial lung disease.\n\nRenal failure. Neuromuscular disease. Pregnancy. Expected OLV duration less than 30 minutes (\\\u003C 30 min)",{"count":303,"type":22},60,[62],"Brief Summary (Kısa Özet)The purpose of this study is to evaluate the safety and efficacy of a cerebral oximetry-guided low fraction of inspired oxygen (FiO\\_2) ventilation strategy compared to a standard high FiO\\_2 strategy in patients undergoing elective thoracic surgery requiring one-lung ventilation (OLV).Oxygen toxicity and related postoperative pulmonary complications remain significant risks during thoracic anesthesia. While standard protocols often rely on high inspired oxygen concentrations to maintain peripheral oxygen saturation (SpO\\_2), this approach may induce hyperoxia. Conversely, lowering FiO\\_2 arbitrarily can increase the risk of hypoxemia or compromise tissue oxygenation. This prospective, parallel-group, 1:1 randomized, single-blind clinical trial aims to safely reduce intraoperative oxygen exposure by using regional cerebral oxygen saturation (rSO\\_2) monitoring as a physiological guide.A total of 60 participants aged 18 and older, classified as ASA I-III and scheduled for elective thoracic surgery, will be randomly assigned to one of two arms:Experimental Group (Guided Low FiO\\_2 Strategy): Ventilation will be initiated at a low FiO\\_2 of 0.5. The FiO\\_2 level will not be increased unless peripheral saturation (SpO\\_2) falls below 90% or cerebral oxygenation (rSO\\_2) drops below 80% of the patient's baseline value.Active Comparator Group (Standard Strategy): Patients will receive conventional anesthesia management, maintaining standard high FiO\\_2 levels to keep SpO\\_2 above 90% without cerebral oximetry guidance.The primary outcomes to be measured are the incidence of cerebral desaturation during the perioperative period and the incidence of postoperative delirium assessed via the 3D-CAM tool until hospital discharge. Secondary outcomes include intraoperative hemodynamic stability, arterial blood gas parameters (PaO\\_2, PaCO\\_2, pH, lactate), incidence of hypoxemia, total one-lung ventilation duration, postoperative cognitive dysfunction (POCD), and lengths of stay in both the intensive care unit (ICU) and the hospital.By utilizing real-time non-invasive cerebral oximetry, the study intends to demonstrate a safe ventilation protocol that minimizes oxygen toxicity without compromising cerebral oxygenation or clinical recovery outcomes.",[31,224],"2026-06-16",{"date":288,"type":43},{"date":310,"type":22},"2026-06-15",{"date":312,"type":22},"2026-08-15",{"name":314,"class":50},"Dicle University",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":322,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":325,"studyType":169,"phases":4,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":344,"locationsCount":51},"100641814","perioperative-quantitative-sensory-testing-and-incision-pain-mapping-in-thoracic-surgery-100641814","NCT07653932","Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery","Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study","Inclusion Criteria:\n\n1. Male\n2. Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.\n3. American Society of Anesthesiologists physical status I to III.\n4. Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.\n5. Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.\n\n3\\. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.\n\n4\\. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.\n\n5\\. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.\n\n6\\. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.\n\n7\\. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.\n\n8\\. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.","MALE",{"count":324,"type":22},46,"3 Months","Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.\n\nThis prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.\n\nThe primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.\n\nThis study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.",[116,328,31,329,330,331],"Chronic Postsurgical Pain","Lung Resection","Mechanical Hyperalgesia","Central Sensitization",[333,334,335,336,337],"Quantitative sensory testing","QST","Incision pain mapping","Thoracoscopic surgery","Perioperative pain phenotype","2026-06-13",{"date":340,"type":43},"2026-06-17",{"date":342,"type":22},"2026-06-08",{"date":72,"type":22},{"name":345,"class":50},"Tongji Hospital",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":51},"100642751","wearable-device-based-early-warning-of-postoperative-complications-in-thoracic-surgery-100642751","NCT07646730","Wearable Device-Based Early Warning of Postoperative Complications in Thoracic Surgery","Development and Validation of a Wearable Device-Based Early Warning Model for Postoperative Complications in Thoracic Surgery: A Retrospective and Prospective Cohort Study","wearable","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Hospitalized in the Department of Thoracic Surgery of Tongji Hospital and scheduled to undergo thoracic surgery.\n3. Able to wear the study-designated wearable device after hospital admission and expected to continue wearing the device and\u002For uploading data within 30 days after discharge.\n\nExclusion Criteria:\n\n1. Patients or family members are unwilling to wear the wearable device or unable to meet the required wearing time.\n2. Severe or unstable psychiatric disease, such as severe depression or schizophrenia.\n3. Pregnancy or lactation.\n4. Allergy to the watch strap material or local skin conditions that prevent wearing the device.\n5. Unable to complete follow-up within 30 days after discharge.",{"count":355,"type":22},650,"After thoracic surgery, some patients may develop complications such as lung infection, abnormal heart rhythm, fluid around the lung, prolonged air leak, wound infection, emergency department visits, or hospital readmission. These problems may not be found early if monitoring is only done during routine vital sign checks or follow-up visits.\n\nThis study will evaluate whether data collected by a wearable device can help identify early warning signs of postoperative complications in patients undergoing thoracic surgery. The wearable device will collect information such as heart rate, oxygen level, skin temperature, physical activity, sleep, and wearing status.\n\nThe study includes two parts. First, the researchers will review previously collected wearable device and medical record data to develop an early warning model. Second, new patients undergoing thoracic surgery will wear the device from hospital admission until about 30 days after discharge. The model will then be tested to see how well it predicts complications that require medical intervention within 30 days after surgery.\n\nThe main goal is to evaluate how accurately the wearable device-based model can identify patients who develop postoperative complications and how early the model can provide a warning before the complication is clinically confirmed.",[358,31,359],"Postoperative Complications","Perioperative Monitoring",[361,362,358,31],"Wearable Device","Early Warning Model","2026-06-12",{"date":310,"type":43},{"date":366,"type":43},"2025-12-16",{"date":368,"type":22},"2026-12-15",{"name":345,"class":50},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":51},"100637667","acbt-with-incentive-spirometry-versus-high-frequency-chest-wall-oscillation-after-thoracic-surgery-100637667","NCT07619716","ACBT With Incentive Spirometry Versus High-Frequency Chest Wall Oscillation After Thoracic Surgery","Effects of Active Cycle of Breathing Techniques With Incentive Spirometry Versus High-Frequency Chest Wall Oscillation on Cough, Sputum, Pulmonary Function Test and Patient Satisfaction After Thoracic Surgery","Inclusion Criteria:\n\n* Adults aged 18-40 years\n* Patients scheduled for elective thoracic surgery (e.g., lobectomy, pneumonectomy, thoracotomy, or VATS)\n* Hemodynamically stable in the postoperative period\n* Cognitively and physically able to perform breathing exercises and use devices (incentive spirometer\u002FHFCWO vest)\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Pre-existing severe pulmonary diseases (e.g., COPD, cystic fibrosis, bronchiectasis)\n* Contraindications to HFCWO (e.g., recent rib fractures, chest wall trauma, unstable cardiovascular status)\n* Cognitive, neuromuscular, or musculoskeletal impairments limiting participation in interventions\n* Prolonged mechanical ventilation (\\>24 hours postoperatively)\n* Active pulmonary infection or hemoptysis within one week after surgery","40 Years",{"count":379,"type":22},42,[62],"This randomized clinical trial aims to compare the effectiveness of Active Cycle of Breathing Techniques combined with Incentive Spirometry (ACBT + IS) versus High-Frequency Chest Wall Oscillation (HFCWO) in patients undergoing thoracic surgery. Postoperative pulmonary complications such as reduced lung function, ineffective cough, and sputum retention are common after thoracic procedures and can delay recovery. A total of 42 participants will be randomly allocated into two groups: one receiving ACBT with Incentive Spirometry and the other receiving HFCWO, along with standard postoperative care. Outcomes including cough effectiveness, sputum clearance, pulmonary function tests, and patient satisfaction will be assessed at baseline, postoperative day 3, and day 5. The study aims to determine the more effective airway clearance technique to improve respiratory outcomes and enhance patient recovery following thoracic surgery.",[31],[384],"Thoracic Surgery Postoperative,ACBT","2026-06-01",{"date":387,"type":43},"2026-06-02",{"date":389,"type":22},"2026-06",{"date":391,"type":22},"2026-08-29",{"name":393,"class":50},"Riphah International University",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100638234","hyperangulated-vs-standard-videolaryngoscopy-vs-direct-laryngoscopy-for-double-lumen-endobronchial-tube-intubation-100638234","NCT07614529","Hyperangulated vs Standard Videolaryngoscopy vs Direct Laryngoscopy for Double-Lumen Endobronchial Tube Intubation","Evaluation of Efficacy and Safety of Hyperangulated and Standard Curvature Blade Video Laryngoscopy Versus Direct Laryngoscopy for Double-Lumen Endobronchial Tube Intubation","Inclusion Criteria:\n\n* Age 18 years or older\n* Written informed consent obtained prior to surgery\n* ASA physical status class I, II, or III\n* Scheduled for elective thoracic surgery requiring one-lung ventilation and double-lumen endobronchial intubation\n\nExclusion Criteria:\n\n* Age under 18 years\n* Refusal or inability to provide informed consent\n* ASA physical status class IV or above\n* Emergency surgery\n* Anticipated difficult airway, defined by any of the following: Mallampati score 4, thyromental distance less than 6.5 cm, restricted mouth opening, or BMI greater than 30 kg\u002Fm²\n* History of upper airway surgery\n* Significant upper airway obstruction or stridor\n* Pregnancy",{"count":167,"type":22},[62],"This is a prospective, randomized, single-center, three-arm, open-label, low-risk medical device clinical study conducted at the Department of Anesthesiology and Reanimation, Trakya University Medical Faculty.\n\nThe study aims to compare the efficacy, safety, and clinical usability of three laryngoscopy methods for double-lumen endotracheal tube (DLT) intubation in patients undergoing elective thoracic surgery requiring one-lung ventilation: (i) C-MAC hyperangulated (D-blade) videolaryngoscopy, (ii) C-MAC Macintosh blade videolaryngoscopy, and (iii) direct Macintosh laryngoscopy.\n\nThe primary outcome is the total time to successful DLT placement (in seconds), defined as the interval from the end of mask ventilation to fiberoptic bronchoscopic confirmation of correct tube position. Secondary outcomes include glottic visualization quality (POGO score and Cormack-Lehane grade), intubation difficulty (Intubation Difficulty Scale), number of intubation attempts, need for auxiliary maneuvers, intubation-related complications, malposition rate, and postoperative airway symptoms (sore throat, dysphonia) assessed at 1, 6, and 24 hours postoperatively.\n\nEligible patients are adults (≥18 years), ASA class I-III, scheduled for elective thoracic surgery requiring one-lung ventilation. Patients with anticipated difficult airway, emergency surgery, pregnancy, or prior upper airway surgery are excluded. A total of 180 patients will be enrolled and randomized 1:1:1 into three groups (60 per group) using computer-generated block randomization.",[405,406,31,407],"Endobronchial Intubation","Double Lumen Tube Intubation","One Lung Ventillation (OLV)",[409,410,411,412,413,414],"double-lumen endotracheal tube","videolaryngoscopy","direct laryngoscopy","C-MAC","thoracic anesthesia","one-lung ventilation","2026-05-28",{"date":417,"type":43},"2026-05-29",{"date":99,"type":22},{"date":420,"type":22},"2029-01-15",{"name":422,"class":50},"Trakya University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":430,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":432,"conditions":433,"keywords":438,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":51},"100638881","the-impact-of-video-assisted-thoracic-surgery-and-regional-anaesthesia-on-postoperative-opioid-consumption-and-pain-scores-100638881","NCT07578545","The Impact of Video-assisted Thoracic Surgery and Regional Anaesthesia on Postoperative Opioid Consumption and Pain Scores","The Effect of Paravertebral Block, Intertransverse Block, and Erector Spinae Plane Block on Postoperative Opioid Consumption and Pain Scores in Video-assisted Thoracic Surgery: a Prospective Observational Study","Inclusion Criteria:\n\n* aged 18-75 years\n* American Society of Anaesthesiology (ASA) score I-III\n* body mass index (BMI) \\\u003C35kg\u002Fm2\n* scheduled for elective VATS\n\nExclusion Criteria:\n\n* ASA score ≥4\n* BMI ≥35 kg\u002Fm2\n* declining to give written informed consent\n* controendications for block application\n* inability to undergo block application\n* history neurological disease or peripheral nerve disease\n* history of chronic opioid use\n* history of severe liver or kidney failure\n* patients admitted to the intensive care unit postoperatively intubated",{"count":431,"type":22},96,"This present study aims is to compare the effects of ultrasound-guided paravertebral block, intertransverse process block, and erector spinae plane block on postoperative opioid consumption, and pain scores in patients undergoing VATS.",[31,434,435,436,437],"Videoassisted Thoracoscopic Surgery,One-lung Ventilation","Regional Anaesthesia","Postoperative Analgesia","Pain Score",[439,440,441,442,443],"videoassisted thoracoscopic surgery","regional anaesthesia","postoperative analgesia","chronic pain","quality of recovery","2026-05-06",{"date":446,"type":43},"2026-05-11",{"date":448,"type":43},"2026-05-04",{"date":450,"type":22},"2026-11-04",{"name":452,"class":294},"Antalya Training and Research Hospital",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":461,"maxAge":377,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":470,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":51},"100597815","evaluation-of-virtual-reality-for-reducing-opioid-use-after-cardiac-and-thoracic-surgery-100597815","NCT07063394","Evaluation of Virtual Reality for Reducing Opioid Use After Cardiac and Thoracic Surgery","Evaluation of the Efficacy of Virtual Reality as a Therapeutic Method to Reduce Opioid Consumption in Postoperative Cardiac and Thoracic Surgery","VR-USP","Inclusion Criteria:\n\n* Patients undergoing elective cardiac or thoracic surgeries at the Heart Institute (InCor) of the Hospital das Clínicas of the University of São Paulo.\n* Eligible thoracic surgeries include: pulmonary decortication, thoracic sympathectomy, video-assisted thoracoscopic surgery (VATS), pulmonary biopsy, and pectus excavatum repair using the Nuss procedure.\n* Patients aged between 16 and 40 years.\n* Preserved cognitive function, indicated by a Mini-Mental State Examination (MMSE) score of ≥ 25.\n\nExclusion Criteria:\n\n* Visual impairments.\n* Cognitive impairment (MMSE ≤ 24).\n* Severe upper limb motor limitations.\n* Claustrophobia.\n* Spatial disorientation.\n* Motion sickness or vestibular disorders.\n* Infectious or contagious diseases.","16 Years",{"count":303,"type":22},[62],"This clinical trial aims to evaluate the efficacy of virtual reality (VR) as an adjunctive therapeutic method to reduce opioid consumption during the postoperative period of cardiac and thoracic surgeries. Conducted at InCor\u002FHCFMUSP, this single-center, prospective, randomized trial will include 60 patients aged 16 to 40 undergoing procedures such as valve replacements, pulmonary decortication, and video-assisted thoracic surgeries.\n\nPatients will be randomized into three groups. The Interactive VR group receives standard anesthesia protocol combined with interactive VR therapy using games and immersive environments. The Passive VR group receives standard protocol combined with passive 360-degree immersive videos. The Control group receives standard anesthesia protocol without VR intervention. The intervention occurs in three daily sessions lasting 30-45 minutes each over the first five postoperative days or until hospital discharge.\n\nThe primary objective is to measure the reduction in total opioid consumption through medical prescriptions and patient-controlled analgesia (PCA) pump usage. Secondary objectives include pain intensity assessed by the Visual Analogue Scale (VAS), incidence of postoperative nausea and vomiting (PONV), duration of mechanical and non-invasive ventilation, length of stay in the ICU and hospital, occurrence of paralytic ileus, patient satisfaction, and cognitive status using the Mini-Mental State Examination (MMSE).\n\nOpioids are standard for postoperative pain but are associated with adverse effects like respiratory depression. VR offers an innovative approach by creating immersive environments that serve as cognitive distractions to modulate pain perception and reduce anxiety. The study anticipates that VR will enhance pain control and improve recovery metrics, serving as a safe and scalable complement to traditional postoperative management.",[466,31,467,468,469],"Heart Surgery","Opioid","Virtual Reality","Pain",[471,31,467,468,469],"Heart surgery","2026-04-10",{"date":474,"type":43},"2026-04-15",{"date":476,"type":43},"2024-12-10",{"date":478,"type":22},"2027-12-30",{"name":480,"class":294},"Filomena R B G Galas",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":496,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":4},"100628764","ultrasound-guided-rhomboid-intercostal-block-versus-thoracic-paravertebral-block-for-vats-analgesia-100628764","NCT07465887","Ultrasound-Guided Rhomboid-Intercostal Block Versus Thoracic Paravertebral Block for VATS Analgesia","Comparison of the Ultrasound-Guided Rhomboid-Intercostal Block (RIB) Versus Thoracic Paravertebral Block (PVB) for Postoperative Analgesia in Video-Assisted Thoracoscopic Surgery (VATS): A Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults (18-85 years old),\n* ASA physical status I-III\n* scheduled for elective 3-port unilateral VATS.\n\nExclusion Criteria:\n\n* Allergy to local anesthetics\n* infection at the injection site\n* coagulation disorders\n* severe neurological disorder\n* obesity (BMI \\> 35)\n* opioid addiction\n* conversion to open thoracotomy, admission to ICU.",{"count":303,"type":22},[62],"Purpose of the study The goal of this research is to see which of two nerve-numbing techniques-the Rhomboid-Intercostal Block (RIB) or the Thoracic Paravertebral Block (PVB)-works better to control pain after chest surgery (specifically, video-assisted thoracoscopic surgery, or VATS). Both techniques use numbing medication to block pain signals after the operation.\n\nWho can participate? The researchers are looking for adults between 18 and 85 years old who are scheduled for a specific type of chest surgery (a 3-port VATS procedure).\n\nHow will the research happen? Participants will be put into two equal groups by chance. One group will receive the RIB technique, and the other group will receive the PVB technique. Both procedures are done under ultrasound guidance after the completion of surgery, while the patient is still asleep. The pain levels of the participants will be measured at rest and when taking deep breaths at several times during the first 24 hours after surgery.\n\nWhy is this study useful? This study aims to find out which pain relief method is more effective and if one results in fewer side effects, such as nausea or the need for stronger pain medications (opioids). These results will possibly help doctors provide better comfort to patients recovering from chest surgery in the future.",[116,31,492,493,494,495],"Thoracic Surgery, Video Assisted","Ultrasound Guided","Paravertebral Thoracic Block","Rhomboid Intercostal Block",[122,497,494,498,436],"Rhomboid-intercostal Block","Regional Anesthesia","2026-03-18",{"date":501,"type":43},"2026-03-20",{"date":503,"type":22},"2026-03-09",{"date":505,"type":22},"2027-03",{"name":507,"class":50},"Georgios Kotsovolis",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":515,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":51},"100612601","thoracic-surgery-by-shurui-single-port-surgical-robot-100612601","NCT07255703","Thoracic Surgery by SHURUI Single-Port Surgical Robot","Thoracic Surgery by SHURUI Single-Port Surgical Robot: A Prospective Single Centre Study","Inclusion criteria:\n\n1. Age between 18 - 75 years;\n2. Subjects need to undergo endoscopic surgery and meet one of the following indications for surgical treatment:\n\n   * Lobectomy, segmentectomy wedge resection of lung: Clinically diagnosed resectable early stage non-small cell lung carcinoma; oligometastatic cancer to the lung;\n   * Mediastinal mass resection: Clinically diagnosed mediastinal tumour (benign or malignant) that are indicated for resection;\n3. Preoperative ASA grade: Grade I-III;\n4. Subject voluntarily participates in the clinical trial, and agrees or his\u002Fher guardian agrees and signs the informed consent.\n\nExclusion criteria:\n\n1. Subjects with a previous history of thoracic surgery or other malignant tumor which, in the judgement of the investigator, make them unsuitable for enrolment;\n2. Subjects with severe co-morbidities or organ dysfunction (heart, lung, liver, brain, kidney, etc.) or deemed too weak\u002F unsuitable for general anesthesia or operation;\n3. Non-correctable coagulopathy and severe bleeding tendency；\n4. Emergency surgery;\n5. Severe obesity with BMI ≥30 kg\u002Fm2;\n6. Subjects with severe allergic constitution, suspected or confirmed alcohol, drug addiction;\n7. Other circumstances in which the investigator considered participation in this clinical trial inappropriate.",{"count":5,"type":22},"The introduction of single-port surgical robot has been a transformative breakthrough in the medical field, representing a significant advancement in minimally invasive procedures. One notable innovation is the SHURUI single-port surgical robot (SP), developed by Beijing Surgerii Robotics Company Limited. The SHURUI SP represents a cutting-edge technology in the field. This system features snake-like surgical instruments utilizing \"dual continuum mechanism\", which enables precise single-port procedures with wide range of motion and high load capacity.\n\nThe SHURUI SP has been cleared by the National Medical Products Administration (NMPA) of China for use in urology and gynecology and has completed clinical trials for general surgery and thoracic surgery. It is China's first and the world's second approved single-port surgical robot. Compared to multi-port surgical robots, it can provide patients with less trauma, fewer complications, and faster recovery.\n\nThe SHURUI SP has also achieved significant breakthroughs in clinical applications. It conducted the world's first randomized controlled clinical trial on single-port robotic urologic surgery and introduced a series of innovative surgical paradigms. These include the world's first single-port sleeve lobectomy, single-port retroperitoneal adrenalectomy, single-port retroperitoneal partial nephrectomy, single-port distal gastrectomy (Billroth I anastomosis), and single-port total gastrectomy.\n\nOur centre is the first robotic surgical centre in Hong Kong since 2005. Over the years, investigators have established our centre to be one of the leading centre in Hong Kong and the region, with involvement in various new development in thoracic robotic procedures, publications and books, and more recently in robotic endo-lumenal procedures.\n\nIn this study, investigators evaluate the early surgical outcome and objective functional outcome of patients undergoing robotic thoracic surgery by SHURUI SP.",[31],{"date":501,"type":43},{"date":520,"type":22},"2026-04-01",{"date":522,"type":22},"2026-11-30",{"name":524,"class":50},"Chinese University of Hong Kong",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":51},"100597831","sensory-anesthesia-achieved-through-different-paravertebral-block-approaches-for-post-op-pain-management-after-vats-lung-resection-100597831","NCT07063602","Sensory Anesthesia Achieved Through Different Paravertebral Block Approaches for Post-Op Pain Management After VATS Lung Resection","Sensory Anesthesia Achieved Through Different Paravertebral Block Approaches for Post-Operative Pain Management After Videothoracoscopic Lung Resection","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* American Society of Anesthesiologists (ASA) score 1-3\n\nExclusion Criteria:\n\n* Contraindication to the paravertebral block (coagulopathy, use of anticoagulants or antiplatelet agents other than aspirin that have not been stopped according to hospital guidelines, thoracoscopic visualization of the paravertebral space expected to be difficult or impossible, anterior spinal surgery with potential discontinuity of the paravertebral space)\n* Epidural analgesia preferred (high risk of thoracotomy, marginal lung function)\n* Surgical criteria: conversion to thoracotomy necessary and thoracic epidural or other form of regional analgesia implemented post-operatively\n* Known allergy to local anesthetics\n* Language barrier, psychiatric, physical or mental condition making pain assessment impossible despite prior education\n* Pregnancy\n* Patient refusal to participate",{"count":112,"type":22},"Video-assisted thoracoscopic lung resection (VATS) is a minimally invasive surgical approach frequently used in the treatment of lung cancers. The most commonly used analgesic technique for this surgery is the paravertebral block with a single peroperative injection of local anesthetic. However, a recent study conducted at our institution revealed that this approach provided less relief than expected in some patients. In light of these results, it becomes crucial to distinguish between technical failures (absence of sensitive anesthesia) and the intrinsic limits of the chosen regional analgesia technique (pain originating from an unanesthetized area or pain despite the presence of sensitive anesthesia) in order to better relieve patients.\n\nThis study aims to objectively assess the areas of anesthesia obtained through three methods of paravertebral block to evaluate their respective performance and optimize post-VATS analgesic management.",[31,535,536],"Video-assisted","Paravertebral Block","2026-02-24",{"date":539,"type":43},"2026-02-27",{"date":541,"type":43},"2025-09-10",{"date":543,"type":22},"2026-09-10",{"name":49,"class":50},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":51},"100607123","a-study-of-pain-reduction-after-pulmonary-resection-by-rats-tt-rats-otc-and-hybrid-rats-100607123","NCT07184463","A Study of Pain Reduction After Pulmonary Resection by RATS-TT, RATS-OTC, and Hybrid RATS.","Chronic Pain After Thoracic Surgery: Towards a New Standard? A Comparative Prospective Study of Pain Reduction After Pulmonary Resection by RATS-TT, RATS-OTC, and Hybrid RATS.","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* American Society of Anesthesiologists (ASA) score 1-3\n\nExclusion Criteria:\n\n* Language barrier, psychiatric, physical or mental condition making pain assessment impossible despite prior education\n* Patient refusal to participate\n* Patients reoperated by VATS or thoracotomy in the postoperative period in the context of the occurrence of complications",{"count":553,"type":22},120,"Pulmonary resections are key in treating lung neoplasms, with techniques adapted to tumor size and location. Minimally invasive approaches like VATS have replaced open thoracotomy, but intercostal trocar placement can lead to nerve injury and chronic pain.\n\nRobotic-assisted thoracic surgery (RATS) is usually done via a transthoracic (RATS-TT) approach using intercostal trocars. A newer \"out of cage\" method (RATS-OTC), using subcostal or subxiphoid ports, avoids intercostal access, potentially reducing nerve damage. A French study showed less opioid use and acute pain with RATS-OTC, but chronic pain outcomes are still unknown.\n\nAt CHUM, a hybrid RATS technique (RATS-TTH) is also used-intercostal for instruments, but with out-of-cage specimen extraction-to limit intercostal trauma.",[31,556,557],"Video-assisted Thoracic Surgery","Robotic-assisted Thoracic Surgery",[442],"2026-02-19",{"date":561,"type":43},"2026-02-23",{"date":563,"type":43},"2025-12-05",{"date":565,"type":22},"2027-06",{"name":49,"class":50},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":592,"locationsCount":51},"100623341","non-intubated-versus-intubated-anesthesia-for-thoracoscopic-sublobar-resection-100623341","NCT07395375","Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection","A Multicenter, Randomized, Controlled Trial of Non-Intubated Spontaneous Breathing Anesthesia Versus Intubated Mechanical Ventilation Anesthesia in Thoracoscopic Sublobar Resection: A Stratified Analysis Study Focusing on Safety and Recovery Quality","NIVA-TSLR","Inclusion Criteria:\n\n1. Aged 18 to 80 years (inclusive).\n2. Scheduled for elective, uniportal or single utility port video-assisted thoracoscopic sublobar resection (wedge resection or simple anatomical segmentectomy).\n3. Preoperative CT diagnosis of a peripheral pulmonary nodule meeting: maximum diameter ≤ 2.0 cm and outer edge ≤ 2.0 cm from the visceral pleura.\n4. American Society of Anesthesiologists (ASA) physical status I or II.\n5. Preoperative pulmonary function: FEV1% ≥ 60% of predicted.\n6. Preoperative arterial blood gas analysis (room air): PaO₂ ≥ 80 mmHg and PaCO₂ ≤ 45 mmHg.\n7. Body Mass Index (BMI) between 18.0 and 28.0 kg\u002Fm².\n8. Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Cardiovascular: NYHA class ≥ III, unstable angina, acute myocardial infarction within 3 months, or severe arrhythmia requiring medication.\n2. Respiratory: Severe COPD (GOLD 3 or 4), symptomatic interstitial lung disease, resting SpO₂ \\\u003C 92% on room air, or severe pulmonary hypertension (estimated systolic PAP \\> 50 mmHg).\n3. Airway Risk: Modified Mallampati score ≥ 3, mouth opening \\\u003C 3 cm, or other predictors of difficult airway management.\n4. Radiological: Preoperative CT suggesting extensive pleural adhesion, moderate or large pleural effusion, or mediastinal lymph nodes \\> 1.5 cm short axis.\n5. Contraindications to Regional Anesthesia: Infection\u002Ftumor at the block site, patient refusal, or allergy to local anesthetics.\n6. Coagulopathy: Platelet count \\\u003C 100×10⁹\u002FL, INR \\> 1.5, or use of anticoagulants that cannot be safely discontinued perioperatively.\n7. Other: Severe hepatic or renal dysfunction, previous ipsilateral thoracic surgery, pregnancy or lactation, active psychiatric or cognitive disorders, or participation in another conflicting clinical trial.","80 Years",{"count":577,"type":22},1600,[62],"This is a large clinical study that compares two different types of anesthesia for patients undergoing a specific kind of minimally invasive lung surgery (thoracoscopic sublobar resection) to remove small, early-stage lung nodules.\n\nThe study aims to find out if a newer anesthesia method, known as \"non-intubated anesthesia\" (where patients breathe on their own with the help of a laryngeal mask airway and nerve blocks for pain control), is as safe as the traditional \"intubated anesthesia\" (which uses a breathing tube and a machine to breathe for the patient).\n\nThe main goals of the study are, in order:\n\n1. Safety First: To confirm that the non-intubated method does not lead to more lung complications within 30 days after surgery compared to the traditional method.\n2. Effectiveness: If it is proven safe, the study will then check if patients receiving the non-intubated anesthesia have a better quality of recovery in the first 24 hours after surgery (e.g., less pain, fewer side effects like a sore throat, and a faster return to normal activities).\n\nApproximately 1600 patients from multiple hospitals will be randomly assigned (like flipping a coin) to receive one of the two anesthesia methods. Neither the patients nor the surgeons will be told which group the patient is in when assessing the main outcomes after surgery, to ensure the results are fair and unbiased.\n\nThe results of this study will provide high-quality evidence to help doctors and patients choose the best and most comfortable anesthesia option for this type of lung surgery.",[581,582,31],"Pulmonary Nodules","Lung Neoplasms",[584,585,117,223,123],"Non-intubated Thoracic Surgery","Lung Sublobar Resection","2026-02-06",{"date":588,"type":43},"2026-02-09",{"date":130,"type":22},{"date":591,"type":22},"2027-08-01",{"name":593,"class":50},"The First Affiliated Hospital of Guangzhou Medical University",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":575,"enrollmentInfo":602,"targetDuration":603,"studyType":169,"phases":4,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":51},"100623088","comparison-of-fcv-and-vcv-in-one-lung-ventilation-100623088","NCT07392086","Comparison of FCV and VCV in One-Lung Ventilation","Comparison of the Effects of Flow-Controlled Ventilation (FCV) and Volume-Controlled Ventilation (VCV) on Respiratory Mechanics and Gas Exchange During One-Lung Ventilation: A Multicenter Prospective Observational Study (FCVOLVent)","FCVOLVent","Inclusion Criteria Adult patients aged 18 years and older Patients undergoing thoracic surgery requiring one-lung ventilation (OLV) Requirement for one-lung ventilation for at least 30 minutes American Society of Anesthesiologists (ASA) physical status I-III Provision of written informed consent Patients ventilated with flow-controlled ventilation (FCV) or volume-controlled ventilation (VCV) as part of routine clinical practice\n\nExclusion Criteria Requirement for emergency surgery History of untreated asthma High pulmonary risk, defined as predicted postoperative FEV₁ \\\u003C 20 mL\u002Fkg in males and \\\u003C 18 mL\u002Fkg in females High cardiac risk, including advanced cardiomyopathy with left ventricular ejection fraction \\\u003C 30% Body mass index (BMI) \\> 35 kg\u002Fm² Contraindication to total intravenous anesthesia (TIVA) Evidence of pulmonary infection prior to surgery Presence of other significant pulmonary pathologies (e.g., tuberculosis, bullous lung disease, bronchiectasis) Severe COPD (GOLD stage III-IV) or significant restrictive lung disease Age \\\u003C 18 years or \\> 80 years, or pregnancy ASA physical status IV or higher Uncontrolled arrhythmia or history of myocardial infarction within the past 3 months Inability to provide informed consent",{"count":303,"type":22},"1 Year","One-lung ventilation (OLV) is commonly used during thoracic surgery but may negatively affect lung mechanics and gas exchange. Different ventilation strategies are used during OLV, and their effects on respiratory parameters remain an important clinical concern.\n\nFlow-controlled ventilation (FCV) is a newer ventilation mode that allows precise control of inspiratory and expiratory flow, potentially improving lung mechanics and gas exchange. Volume-controlled ventilation (VCV) is a widely used conventional ventilation strategy during thoracic anesthesia.\n\nThe FCVOLVent study is a multicenter, prospective observational study designed to compare the effects of FCV and VCV during one-lung ventilation in adult patients undergoing thoracic surgery. Patients will be ventilated with either FCV or VCV as part of routine clinical practice.\n\nThe study aims to evaluate respiratory mechanics and oxygenation parameters, including the PaO₂\u002FFiO₂ ratio, airway pressures, lung compliance, and mechanical power during surgery. Data will be collected at predefined time points during one-lung ventilation.\n\nThe results of this study are expected to provide real-world clinical evidence on the potential advantages and limitations of flow-controlled ventilation compared with volume-controlled ventilation during one-lung ventilation.",[606,31,607],"One-lung Ventilation (OLV)","Respiratory Mechanics",[609,610,611,612],"Flow-Controlled Ventilation","Thoracic Anesthesia","Volume-Controlled Ventilation","One-Lung Ventilation","2026-01-29",{"date":586,"type":43},{"date":616,"type":43},"2026-01-01",{"date":618,"type":22},"2026-12-01",{"name":620,"class":50},"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":51},"100582571","perioperative-inhaled-therapy-in-carcinological-thoracic-surgery-in-patients-at-high-risk-of-postoperative-pulmonary-complications-100582571","NCT06865040","Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications","TICTAC","Inclusion Criteria:\n\n* Adult (\\>18 years)\n* Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route\n* Naïve to long-term inhaled bronchodilator therapy\n* High risk of post-operative pulmonary complications (Pre-operative FEV1 \\\u003C 80%)\n\nExclusion Criteria:\n\n* Patient refusal\n* Pregnancy\n* Emergency surgery\n* Patient with a physiological status of WHO IV or ASA ≥ IV\n* Asthma\n* Patients treated with long-acting bronchodilators\n* Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \\\u003C 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \\\u003C 3 months\n* High-grade unresponsive conductive disorders or unstable arrhythmia\n* Thyrotoxicosis, pheochromocytoma\n* Unbalanced diabetes\n* Hypersensitivity to ß-2 mimetics or lactose\n* Current participation in a trial of another drug therapy",{"count":629,"type":22},266,[62],"The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications",[31,633],"Postoperative Pulmonary Complications (PPCs)",[635,636,637,638,639],"Thoracic surgery","postoperative pulmonary complications","Inhaled therapy","bronchodilators","B2 mimetics","2026-01-15",{"date":642,"type":43},"2026-01-16",{"date":644,"type":43},"2025-07-31",{"date":646,"type":22},"2028-09",{"name":648,"class":50},"Centre Hospitalier Universitaire, Amiens",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":657,"targetDuration":4,"studyType":23,"phases":659,"briefSummary":661,"conditions":662,"keywords":664,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100619659","phase-4-a-randomized-controlled-clinical-trial-comparing-remimazolam-besylate-combined-with-alfentanil-versus-propofol-combined-with-alfentanil-for-anesthesia-in-thoracic-surgery-100619659","NCT07347496","A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery","A Randomized, Single-blind, Parallel-controlled Clinical Study to Evaluate the Safety and Efficacy of Remimazolam Besylate Combined With Alfentanil in Anesthesia for Thoracic Surgery","RAA-TS","Inclusion Criteria:\n\n* Patients scheduled for elective thoracic surgery (e.g., pulmonary lobectomy, esophagectomy) under general anesthesia with preserved spontaneous respiration.\n* American Society of Anesthesiologists (ASA) physical status class I-III.\n* Age between 18 and 75 years.\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction (e.g., Child-Pugh class C, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n* Severe respiratory dysfunction (e.g., COPD GOLD stage 3-4, severe asthma).\n* Anticipated difficult airway (e.g., Mallampati class IV, history of difficult intubation).\n* Known allergy or hypersensitivity to benzodiazepines, opioids, or propofol.\n* Pregnancy or lactation.\n* Participation in another interventional clinical trial within the past 3 months.\n* Mental illness or inability to cooperate with assessments.",{"count":658,"type":22},50,[660],"PHASE4","Title: A Clinical Study Comparing Two Anesthesia Methods for Chest Surgery\n\nWhy is this study being done? Chest surgeries (like lung surgery) require safe and stable anesthesia. Currently, a drug called propofol combined with an opioid painkiller (alfentanil) is commonly used. However, propofol can sometimes cause low blood pressure and low oxygen levels. A newer drug called remimazolam may cause fewer of these side effects. This study aims to compare the safety and effectiveness of remimazolam (combined with alfentanil) versus propofol (combined with alfentanil) for anesthesia during chest surgery.\n\nWhat will happen in the study?\n\nPatients scheduled for elective chest surgery will be invited to participate. If they agree, they will be randomly assigned (like flipping a coin) to one of two groups:\n\n* Group 1: Will receive remimazolam and alfentanil for anesthesia.\n* Group 2: Will receive propofol and alfentanil for anesthesia (standard care).\n\nThe anesthesiologist will carefully monitor patients during and after surgery. We will mainly compare how often patients in each group experience two safety issues: low oxygen levels in the blood and low blood pressure. We will also record recovery times, drug doses, side effects, and ask patients and surgeons about their satisfaction.\n\nWho can participate? Adults aged 18-65 who are scheduled for elective chest surgery and are in relatively stable health (ASA physical status I-III).\n\nWhere is the study taking place? This study will be conducted in the Department of Anesthesiology at The First Affiliated Hospital of Xinxiang Medical College, Henan, China.\n\nEthics Approval:\n\nThis study has been reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Xinxiang Medical College (Approval Number: (2025) Medical Ethics Committee Approval No. 29).",[31,224,663],"Non-intubated Anesthesia",[665,666,667,668,669,670,671],"Remimazolam","Alfentanil","Propofol","Non-intubated","Tubeless Anesthesia","Spontaneous Ventilation Spontaneous Ventilation","Total Intravenous Anesthesia Total Intravenous Anesthesia","2026-01-09",{"date":642,"type":43},{"date":130,"type":22},{"date":676,"type":22},"2028-05-31",{"name":678,"class":50},"The First Affiliated Hospital of Xinxiang Medical College"]